GlassScriptPhysician profile
Remberto Bitar
NPI 1386609899
$86,793.00
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $40K · 2021: $3,716 · 2022: $200.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $64,562.31 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,542.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $4,412.16 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $4,409.93 | 2019-2020 | |
| Viiv Healthcare Company | $3,637.86 | 2019 | |
| Mylan Specialty L.P. | $3,165.14 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $150.87 | 2019-2022 | |
| Inspire Medical Systems, INC. | $123.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.49 | 2019-2020 | |
| Pfizer INC. | $73.73 | 2019 | |
| Harmony Biosciences LLC | $69.20 | 2020 | |
| Jazz Pharmaceuticals INC. | $67.31 | 2020 | |
| Insmed, INC. | $56.77 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $51.21 | 2019 | |
| Grifols USA, LLC | $46.84 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $32.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $31.44 | 2020 | |
| Circassia INC. | $28.00 | 2019-2020 | |
| Electromed, INC. | $27.82 | 2021 | |
| Genentech USA, INC. | $26.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.89 | 2019 | |
| Vifor Pharma, INC. | $24.60 | 2019 | |
| Philips North America LLC | $20.87 | 2019 | |
| Melinta Therapeutics, LLC | $18.48 | 2021 | |
| Genzyme Corporation | $18.45 | 2019 | |
| Amarin Pharma, INC. | $16.85 | 2020 | |
| Resmed Corp | $16.05 | 2019 | |
| Advanced Respiratory, INC | $13.24 | 2019 | |
| Merck Sharp & Dohme LLC | $12.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.60 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Remberto Bitar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.